376 related articles for article (PubMed ID: 28087666)
1. Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.
Vander Heiden JA; Stathopoulos P; Zhou JQ; Chen L; Gilbert TJ; Bolen CR; Barohn RJ; Dimachkie MM; Ciafaloni E; Broering TJ; Vigneault F; Nowak RJ; Kleinstein SH; O'Connor KC
J Immunol; 2017 Feb; 198(4):1460-1473. PubMed ID: 28087666
[TBL] [Abstract][Full Text] [Related]
2. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.
Stathopoulos P; Kumar A; Nowak RJ; O'Connor KC
JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878127
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.
Stathopoulos P; Kumar A; Heiden JAV; Pascual-Goñi E; Nowak RJ; O'Connor KC
Ann N Y Acad Sci; 2018 Jan; 1412(1):154-165. PubMed ID: 29381221
[TBL] [Abstract][Full Text] [Related]
4. [Clinical features of myasthenia related with autoantibodies to muscle specific tyrosine kinase (MuSK)].
Sanadze AG; Sidnev DV; Karganov MIu
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):72-6. PubMed ID: 21311492
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
Fichtner ML; Jiang R; Bourke A; Nowak RJ; O'Connor KC
Front Immunol; 2020; 11():776. PubMed ID: 32547535
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of immunopathological features of AChR/MuSK autoantibody-negative myasthenia gravis.
Hayashi A; Shiono H; Ohta M; Ohta K; Okumura M; Sawa Y
J Neuroimmunol; 2007 Sep; 189(1-2):163-8. PubMed ID: 17706794
[TBL] [Abstract][Full Text] [Related]
7. Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.
Vrolix K; Fraussen J; Losen M; Stevens J; Lazaridis K; Molenaar PC; Somers V; Bracho MA; Le Panse R; Stinissen P; Berrih-Aknin S; Maessen JG; Van Garsse L; Buurman WA; Tzartos SJ; De Baets MH; Martinez-Martinez P
J Autoimmun; 2014 Aug; 52():101-12. PubMed ID: 24439114
[TBL] [Abstract][Full Text] [Related]
8. High-Throughput Single-Cell Analysis of B Cell Receptor Usage among Autoantigen-Specific Plasma Cells in Celiac Disease.
Roy B; Neumann RS; Snir O; Iversen R; Sandve GK; Lundin KEA; Sollid LM
J Immunol; 2017 Jul; 199(2):782-791. PubMed ID: 28600290
[TBL] [Abstract][Full Text] [Related]
9. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
[TBL] [Abstract][Full Text] [Related]
10. Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.
Yilmaz V; Oflazer P; Aysal F; Durmus H; Poulas K; Yentur SP; Gulsen-Parman Y; Tzartos S; Marx A; Tuzun E; Deymeer F; Saruhan-Direskeneli G
PLoS One; 2015; 10(4):e0123546. PubMed ID: 25893403
[TBL] [Abstract][Full Text] [Related]
11. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
[TBL] [Abstract][Full Text] [Related]
12. [Myasthenia gravis induced by autoantibodies against MuSK].
Shigemoto K; Konishi T; Ohta M
Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361
[TBL] [Abstract][Full Text] [Related]
13. Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis.
Lee JY; Stathopoulos P; Gupta S; Bannock JM; Barohn RJ; Cotzomi E; Dimachkie MM; Jacobson L; Lee CS; Morbach H; Querol L; Shan JL; Vander Heiden JA; Waters P; Vincent A; Nowak RJ; O'Connor KC
Ann Clin Transl Neurol; 2016 Jun; 3(6):443-54. PubMed ID: 27547772
[TBL] [Abstract][Full Text] [Related]
14. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
Shiraishi H; Motomura M; Yoshimura T; Fukudome T; Fukuda T; Nakao Y; Tsujihata M; Vincent A; Eguchi K
Ann Neurol; 2005 Feb; 57(2):289-93. PubMed ID: 15668981
[TBL] [Abstract][Full Text] [Related]
15. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
16. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
17. T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients.
Marino M; Maiuri MT; Di Sante G; Scuderi F; La Carpia F; Trakas N; Provenzano C; Zisimopoulou P; Ria F; Tzartos SJ; Evoli A; Bartoccioni E
J Autoimmun; 2014 Aug; 52():113-21. PubMed ID: 24397960
[TBL] [Abstract][Full Text] [Related]
18. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
Deymeer F; Gungor-Tuncer O; Yilmaz V; Parman Y; Serdaroglu P; Ozdemir C; Vincent A; Saruhan-Direskeneli G
Neurology; 2007 Feb; 68(8):609-11. PubMed ID: 17310034
[TBL] [Abstract][Full Text] [Related]
19. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis.
Lauriola L; Ranelletti F; Maggiano N; Guerriero M; Punzi C; Marsili F; Bartoccioni E; Evoli A
Neurology; 2005 Feb; 64(3):536-8. PubMed ID: 15699390
[TBL] [Abstract][Full Text] [Related]
20. Myasthenia gravis experimentally induced with muscle-specific kinase.
Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
